TrkA Co-Receptors: The Janus Face of TrkA?
TrkA
aggressiveness
co-receptors
drug resistance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Mar 2023
23 Mar 2023
Historique:
received:
17
02
2023
revised:
18
03
2023
accepted:
21
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Larotrectinib and Entrectinib are specific pan-Trk tyrosine kinase inhibitors (TKIs) approved by the Food and Drug Administration (FDA) in 2018 for cancers with an NTRK fusion. Despite initial enthusiasm for these compounds, the French agency (HAS) recently reported their lack of efficacy. In addition, primary and secondary resistance to these TKIs has been observed in the absence of other mutations in cancers with an NTRK fusion. Furthermore, when TrkA is overexpressed, it promotes ligand-independent activation, bypassing the TKI. All of these clinical and experimental observations show that genetics does not explain all therapeutic failures. It is therefore necessary to explore new hypotheses to explain these failures. This review summarizes the current status of therapeutic strategies with TrkA inhibitors, focusing on the mechanisms potentially involved in these failures and more specifically on the role of TrkA.
Identifiants
pubmed: 37046604
pii: cancers15071943
doi: 10.3390/cancers15071943
pmc: PMC10093326
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Région Hauts de France
ID : ST fellowship
Organisme : Ligue Nationale contre le cancer
ID : ST fellowship
Organisme : Ligue nationale contre le cancer comité du Nord
ID : grant 2022-2023
Organisme : Ligue Nationale contre le cancer comité du Pas de Calais
ID : Grant 2022-2023
Organisme : Cancéropôle Nord Ouest
ID : emerging grant 2021
Organisme : Rotary Club, Nieppe
ID : Ruban Rose grant 2021
Organisme : Contrat de plan Etat Région
ID : CPER cancer 2015-2020
Références
Clin Cancer Res. 1999 Aug;5(8):2205-12
pubmed: 10473107
Endocrinology. 2006 Oct;147(10):4646-54
pubmed: 16809450
Breast Cancer Res Treat. 2020 Feb;179(3):631-642
pubmed: 31823098
Neuron. 2007 Jan 4;53(1):25-38
pubmed: 17196528
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):E297-E306
pubmed: 28039433
Science. 1994 Nov 4;266(5186):816-9
pubmed: 7973638
Eur J Neurosci. 2004 Nov;20(9):2321-35
pubmed: 15525274
J Biol Chem. 2000 Feb 25;275(8):5388-94
pubmed: 10681513
Oncotarget. 2015;6(12):9807-19
pubmed: 25840418
Commun Biol. 2020 Dec 16;3(1):776
pubmed: 33328556
Bioorg Med Chem Lett. 2020 Jan 1;30(1):126775
pubmed: 31699609
Cancer Res. 1999 May 15;59(10):2395-401
pubmed: 10344749
Nat Med. 2019 Sep;25(9):1422-1427
pubmed: 31406350
Mol Cell Biol. 1995 Nov;15(11):6118-27
pubmed: 7565764
Oncogene. 2018 Mar;37(11):1472-1484
pubmed: 29321661
J Manag Care Spec Pharm. 2020 Aug;26(8):981-986
pubmed: 32329651
Int J Biochem Cell Biol. 1998 Mar;30(3):299-305
pubmed: 9611772
J Neurosci. 2006 Nov 15;26(46):11974-86
pubmed: 17108171
Cancer Res. 2007 May 1;67(9):4190-8
pubmed: 17483330
Pharmacol Res Perspect. 2017 Oct;5(5):
pubmed: 28971611
Cancer Biol Ther. 2007 Sep;6(9):1360-7
pubmed: 17786033
J Biol Chem. 1999 Dec 10;274(50):35499-504
pubmed: 10585422
Front Oncol. 2019 Aug 23;9:800
pubmed: 31508364
Oncogene. 2001 Mar 8;20(10):1229-34
pubmed: 11313867
J Pain Res. 2019 Mar 19;12:975-995
pubmed: 30936738
Cancer Lett. 2019 May 1;449:196-206
pubmed: 30771434
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3555-60
pubmed: 11248116
Mol Cell Neurosci. 2010 Nov;45(3):201-12
pubmed: 20600928
Bioorg Med Chem Lett. 2017 Mar 1;27(5):1233-1236
pubmed: 28159414
J Orthop Res. 2010 Mar;28(3):279-83
pubmed: 19824062
Mol Cell. 2005 Oct 28;20(2):301-12
pubmed: 16246731
J Biol Chem. 2013 Apr 19;288(16):11144-54
pubmed: 23471969
Pain. 2013 Jul;154(7):1009-21
pubmed: 23628600
Cancer Lett. 2020 Mar 1;472:81-96
pubmed: 31838083
J Hematol Oncol. 2021 Jan 28;14(1):20
pubmed: 33509252
Acta Pharm Sin B. 2018 Jul;8(4):511-517
pubmed: 30109176
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30
pubmed: 31738426
EMBO Rep. 2005 Oct;6(10):936-41
pubmed: 16113645
Invest New Drugs. 2008 Jun;26(3):241-7
pubmed: 18217204
J Neurosci Res. 2004 Oct 15;78(2):186-92
pubmed: 15378608
Curr Probl Cancer. 2021 Dec;45(6):100734
pubmed: 33865615
Gastroenterology. 2016 Feb;150(2):513-25.e10
pubmed: 26597578
Nat Rev Immunol. 2003 Sep;3(9):745-56
pubmed: 12949498
Sci Rep. 2019 Jan 30;9(1):930
pubmed: 30700786
Nature. 1986 Feb 27-Mar 5;319(6056):743-8
pubmed: 2869410
J Biol Chem. 1995 Apr 7;270(14):7795-8
pubmed: 7536190
Genomics. 1995 Jul 1;28(1):15-24
pubmed: 7590742
J Biol Chem. 2001 May 25;276(21):17864-70
pubmed: 11359788
J Biol Chem. 2007 Mar 9;282(10):7606-15
pubmed: 17215246
Mol Cancer Ther. 2017 Oct;16(10):2130-2143
pubmed: 28751539
Neuron. 1994 Jul;13(1):203-15
pubmed: 7519025
Oxid Med Cell Longev. 2019 Dec 2;2019:2051235
pubmed: 31871542
Science. 1986 Apr 25;232(4749):518-21
pubmed: 3008331
J Biol Chem. 2022 Mar;298(3):101568
pubmed: 35051416
Cell Signal. 2010 Oct;22(10):1437-47
pubmed: 20566383
Cancer Discov. 2017 Sep;7(9):963-972
pubmed: 28578312
Mol Cell Biol. 2000 Dec;20(23):8655-66
pubmed: 11073967
J Med Chem. 2019 Jan 10;62(1):247-265
pubmed: 29672039
Mol Cancer Ther. 2013 Feb;12(2):173-83
pubmed: 23243060
Cancer Res. 2001 Mar 1;61(5):2301-6
pubmed: 11280802
Oncogene. 2003 Aug 28;22(36):5592-601
pubmed: 12944907
J Exp Clin Cancer Res. 2022 Mar 28;41(1):110
pubmed: 35346305
Blood. 2009 Dec 10;114(25):5236-44
pubmed: 19773544
Cancer Cell. 2009 Jul 7;16(1):9-20
pubmed: 19573808
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Mol Biol Cell. 2009 Aug;20(16):3620-7
pubmed: 19553472
Neuron. 1999 Nov;24(3):585-93
pubmed: 10595511
J Biol Chem. 2002 Oct 18;277(42):39274-9
pubmed: 12167657